ANDA 78996, held by Sun Pharmaceutical Industries. Ibandronate Sodium.
As of Nov 21, 2026, ANDA 78996 (Ibandronate Sodium), held by Sun Pharmaceutical Industries, was first approved by FDA on Aug 15, 2012, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 15, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ibandronate SodiumEQ 150MG BASE · tablet;oral | Ibandronate Sodium | Discontinued |
| Feb 3, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 22, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 22, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 22, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 15, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters